Document is current
Any future updates will be listed below
-
Authors
Cordas dos Santos, David M. https://orcid.org/0000-0002-9198-8338
Toenges, Rosa
Bertamini, Luca
Alberge, Jean-Baptiste https://orcid.org/0000-0002-4218-7294
Ghobrial, Irene M. https://orcid.org/0000-0001-7361-3092
- License Information
-
More Information
Article History
Accepted: 6 September 2024
First Online: 16 October 2024
Competing interests
: I.M.G. received honoraria from Celgene, Bristol-Myers-Squibb, Takeda, Amgen, Janssen and Vor Biopharma; had consultancy/advisory roles with Bristol-Myers-Squibb, Novartis, Amgen, Takeda, Celgene, Cellectar, Sanofi, Janssen, Pfizer, Menarini Silicon Biosystems, Oncopeptides, The Binding Site, GSK, AbbVie, Adaptive and 10X Genomics; has received speaker fees from Vor Biopharma and Veeva Systems, Inc.; is a co-founder and equity holder in PreDICTA Biosciences; and her spouse is the CMO and equity holder of Disc Medicine. None of these interests are related to the financing of this Review. D.M.C.d.S., R.T., L.B. and J.-B.A. declare no competing interests.
